volume 21 issue 10 pages 4017-4029

Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine In Vivo

Publication typeJournal Article
Publication date2020-08-17
scimago Q1
wos Q1
SJR1.142
CiteScore9.2
Impact factor5.4
ISSN15257797, 15264602
Materials Chemistry
Polymers and Plastics
Bioengineering
Biomaterials
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an attractive antitumor drug candidate for precision cancer therapy due to its superior selective cytotoxicity in a variety of tum...
Found 
Found 

Top-30

Journals

1
2
International Journal of Pharmaceutics
2 publications, 20%
Future Oncology
1 publication, 10%
Nano Research
1 publication, 10%
Molecular Pharmaceutics
1 publication, 10%
Journal of Immunology Research
1 publication, 10%
mAbs
1 publication, 10%
Journal of Drug Delivery Science and Technology
1 publication, 10%
Cancer Medicine
1 publication, 10%
Russian Chemical Reviews
1 publication, 10%
1
2

Publishers

1
2
3
Elsevier
3 publications, 30%
Taylor & Francis
2 publications, 20%
Springer Nature
1 publication, 10%
American Chemical Society (ACS)
1 publication, 10%
Hindawi Limited
1 publication, 10%
Wiley
1 publication, 10%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 10%
1
2
3
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
10
Share
Cite this
GOST |
Cite this
GOST Copy
Tao Z. et al. Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine In Vivo // Biomacromolecules. 2020. Vol. 21. No. 10. pp. 4017-4029.
GOST all authors (up to 50) Copy
Tao Z., Liu Y., Yang H., Feng Y., Li H., Shi Q., Li S., CHENG J., Lu X. Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine In Vivo // Biomacromolecules. 2020. Vol. 21. No. 10. pp. 4017-4029.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1021/acs.biomac.0c00785
UR - https://doi.org/10.1021/acs.biomac.0c00785
TI - Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine In Vivo
T2 - Biomacromolecules
AU - Tao, Ze
AU - Liu, Yuehua
AU - Yang, Hao
AU - Feng, Yanru
AU - Li, Heng
AU - Shi, Qiuxiao
AU - Li, Shengfu
AU - CHENG, JINGQIU
AU - Lu, Xiaofeng
PY - 2020
DA - 2020/08/17
PB - American Chemical Society (ACS)
SP - 4017-4029
IS - 10
VL - 21
PMID - 32804484
SN - 1525-7797
SN - 1526-4602
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2020_Tao,
author = {Ze Tao and Yuehua Liu and Hao Yang and Yanru Feng and Heng Li and Qiuxiao Shi and Shengfu Li and JINGQIU CHENG and Xiaofeng Lu},
title = {Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine In Vivo},
journal = {Biomacromolecules},
year = {2020},
volume = {21},
publisher = {American Chemical Society (ACS)},
month = {aug},
url = {https://doi.org/10.1021/acs.biomac.0c00785},
number = {10},
pages = {4017--4029},
doi = {10.1021/acs.biomac.0c00785}
}
MLA
Cite this
MLA Copy
Tao, Ze, et al. “Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine In Vivo.” Biomacromolecules, vol. 21, no. 10, Aug. 2020, pp. 4017-4029. https://doi.org/10.1021/acs.biomac.0c00785.